A Closer Look at Spravato (Esketamine)
Topic: How will it be administered?
As the P.R. machine kicks into gear to support the launch of Spravato/Esketamine, the first FDA approved Ketamine-derived treatment, Kevin Nicholson (President, CEO of Ketamine Wellness Centers) digs into the details that tend to receive less attention.
This episode focuses on how Spravato is administered:
- Is intranasal delivery effective?
- What type of clinical environments can provide Spravato to patients?
- What duration of time will patients have to commit to treatment?
Our experienced team of physicians, nurse practitioners, and research staff break down each topic in short, to-the-point podcasts, which you may listen to on your own time by subscribing to Ketamine Wellness Centers on iTunes or tune in by following the KWC blog.